ARMGO is a privately owned, venture-backed, biotech company that is developing small molecule drugs that repair leaky Ryanodine Receptor (RyR) calcium channels associated with human diseases. Our primary focus is on two orphan diseases: the life-threatening cardiac disease Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and the severe muscle disease RYR1-Related Myopathy (RYR1-RM). These two conditions occur due to genetic mutations in the RYR gene: RYR1 in RYR1-RM, and RYR2 in most CPVT cases. ARMGO’s molecules, termed Rycals® are designed to repair leaky RyR channels. Since the cause of the symptoms is abnormal calcium leak due to these mutations, Rycals hold the promise of disease-modifying therapy for these two orphan genetic diseases.